Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Apex Healthcare Bhd's PEG is 1. Apex Healthcare Bhd's 5-Year TTM EBITDA Growth Rate is 16.21.
Apex Healthcare Bhd's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 was RM0.09. Therefore, the Peter Lynch Fair Value for today is RM1.49.
The historical rank and industry rank for Apex Healthcare Bhd's Peter Lynch Fair Value or its related term are showing as below:
XKLS:7090'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.17 Med: 1.85 Max: 2.93
Current: 1.75
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Apex Healthcare Bhd was 2.93. The lowest was 0.17. And the median was 1.85.
XKLS:7090's Price-to-Peter-Lynch-Fair-Value is not ranked
in the Medical Distribution industry.
Industry Median: 1.31
vs XKLS:7090: 1.75
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Apex Healthcare Bhd (XKLS:7090) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 16.21 instead of 15 in this case.
Apex Healthcare Bhd's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
2.61
/
1.49
=
1.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Healthcare Bhd Peter Lynch Fair Value Related Terms
Apex Healthcare Bhd Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Apex Healthcare Bhd's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7090 vs MCK, COR, CAH: Peter Lynch Fair Value Comparison
For the Medical Distribution subindustry, Apex Healthcare Bhd's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Healthcare Bhd Price-to-Peter-Lynch-Fair-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Apex Healthcare Bhd's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Apex Healthcare Bhd's Price-to-Peter-Lynch-Fair-Value falls into.
Apex Healthcare Bhd's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of RM1.49 mean?
Apex Healthcare Bhd (XKLS:7090) has a Peter Lynch Fair Value of RM1.49 as of Jul. 27, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Apex Healthcare Bhd and its competitors. This is 19% below median its historical median of 1.85. Over the past decade, Apex Healthcare Bhd's Peter Lynch Fair Value has ranged from 0.17 to 2.93.
Is Apex Healthcare Bhd's Peter Lynch Fair Value too high?
Apex Healthcare Bhd's current Peter Lynch Fair Value of RM1.49 is 19% below median its 10-year median of 1.85. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 2.93. Overall, Apex Healthcare Bhd has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Apex Healthcare Bhd's Peter Lynch Fair Value compare to MCK and COR?
Apex Healthcare Bhd's Peter Lynch Fair Value of RM1.49 can be compared against companies in the Medical Distribution industry. The industry median Peter Lynch Fair Value is 1.31. Historically, Apex Healthcare Bhd's own Peter Lynch Fair Value has ranged from 0.17 to 2.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Distribution company?
The median Peter Lynch Fair Value among Medical Distribution companies is 1.31, based on 32 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Apex Healthcare Bhd and its competitors. For the Medical Distribution industry, the median Peter Lynch Fair Value is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Healthcare Bhd's current Peter Lynch Fair Value is RM1.49, which is 19% below median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Healthcare Bhd stock overvalued right now?
Apex Healthcare Bhd (XKLS:7090) has a current Peter Lynch Fair Value of RM1.49. The stock's GF Value™ is RM2.27, compared to a current price of RM2.61 — trading 15% above its estimated fair value. The current Peter Lynch Fair Value is RM1.49, which is 19% below median its 10-year median of 1.85. Apex Healthcare Bhd's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Apex Healthcare Bhd (XKLS:7090), the current Peter Lynch Fair Value is RM1.49 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Healthcare Bhd (XKLS:7090) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Healthcare Bhd stock appears to be overvalued.
The current stock price of RM2.61 is trading 15% above its estimated GF Value™ of RM2.27.
Key valuation signals for XKLS:7090:
Peter Lynch Fair Value: RM1.49 (19% below median its 10-year median of 1.85)
GF Value™: RM2.27 vs. price of RM2.61 (15% above fair value)
No single metric tells the full story. See the XKLS:7090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Healthcare Bhd is an investment holding company for a group of companies engaged in the development, manufacturing, marketing, and distribution of pharmaceuticals, diagnostics, consumer healthcare products, and orthopedic devices. It has direct operations in Malaysia, Singapore and Others. The company has two manufacturing plants in Melaka and Penang. It has three segments: Manufacturing, Distribution and Corporate. It derives maximum revenue from Malaysia and also has a presence in Singapore and other couintries.
63GF Score
Get the complete analysis for XKLS:7090
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7090 has been successfully added to your 
